{"id":7862,"date":"2024-12-02T20:58:50","date_gmt":"2024-12-02T12:58:50","guid":{"rendered":"https:\/\/regask.com\/?p=7862"},"modified":"2024-12-02T20:58:50","modified_gmt":"2024-12-02T12:58:50","slug":"approbation-de-lexamen-des-medicaments-nmpa-en-chine","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/china-nmpa-drug-review-approval\/","title":{"rendered":"La NMPA approuve la premi\u00e8re demande d&#039;essai clinique dans le cadre du PI..."},"content":{"rendered":"<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"2451705a-75cb-46e1-baee-db0ea4fb0cfa\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>On November 15, 2024, China\u2019s National Medical Products Administration (NMPA) announced a milestone in its pilot program designed to optimize the review and approval processes for innovative drugs. This initiative aims to streamline clinical trial applications, improving both efficiency and quality.<\/p>\n<h4>Key Highlights<\/h4>\n<ul>\n<li><strong>First Approval:<\/strong><br \/>\nThe first clinical trial application approved under the pilot program is for an injectable drug for advanced solid tumors. The trial will be conducted by <strong>Peking University Cancer Hospital<\/strong>.<\/li>\n<li><strong>Faster Review Process:<\/strong><br \/>\nThe review was completed in just <strong>21 days<\/strong>, showcasing a significant improvement in processing times compared to traditional procedures.<\/li>\n<li><strong>Scope of the Pilot Program:<\/strong>\n<ul>\n<li>A total of <strong>nine clinical trials<\/strong> have been included in the pilot work plan.<\/li>\n<li>Five of these trials have submitted Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE), all of which have been accepted for review.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Enhanced Collaboration:<\/strong><br \/>\nThe program prioritizes closer communication and collaboration among evaluation agencies, local regulatory authorities, applicants, and medical institutions. This approach aims to maintain high-quality standards while expediting the application process.<\/li>\n<\/ul>\n<h4>Implications<\/h4>\n<p>The successful approval under this pilot program marks a promising step in <a href=\"https:\/\/regask.com\/china-cosmetics-monitoring-focus\/\">China\u2019s efforts<\/a> to encourage innovation in drug development. By significantly reducing review timelines and fostering collaboration, the initiative supports the rapid advancement of treatments for critical conditions like advanced tumors.<\/p>\n<h4>Next Steps<\/h4>\n<p>Stakeholders should monitor the progress of the pilot program and its impact on clinical trial efficiency. Companies planning to develop innovative drugs in China may find this program beneficial and should explore opportunities to participate in similar initiatives.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\">\n<div class=\"flex items-center\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le 15 novembre 2024, l&#039;Administration nationale des produits m\u00e9dicaux (NMPA) chinoise a annonc\u00e9 une \u00e9tape importante dans son programme pilote visant \u00e0 optimiser les processus d&#039;examen et d&#039;approbation des m\u00e9dicaments innovants. Cette initiative vise \u00e0 simplifier les demandes d&#039;essais cliniques, am\u00e9liorant ainsi l&#039;efficacit\u00e9 et la qualit\u00e9. Points cl\u00e9s\u00a0: Premi\u00e8re approbation\u00a0: La premi\u00e8re demande d&#039;essai clinique approuv\u00e9e dans le cadre du programme pilote\u2026<\/p>","protected":false},"author":43,"featured_media":7872,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[591,498,497],"class_list":["post-7862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-clinical-trial-regulations","tag-drug-development-regs","tag-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China NMPA&#039;s New Drug Review &amp; Approval Process | RegASK<\/title>\n<meta name=\"description\" content=\"China&#039;s NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/approbation-de-lexamen-des-medicaments-nmpa-en-chine\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves First Clinical Trial Application Under Pilot Program for Innovative Drugs\" \/>\n<meta property=\"og:description\" content=\"China&#039;s NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/approbation-de-lexamen-des-medicaments-nmpa-en-chine\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T12:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"NMPA Approves First Clinical Trial Application Under Pi&hellip;\",\"datePublished\":\"2024-12-02T12:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"keywords\":[\"Clinical Trial Regulations\",\"Drug Development Regs\",\"Oncology\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\",\"name\":\"China NMPA's New Drug Review & Approval Process | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"datePublished\":\"2024-12-02T12:58:50+00:00\",\"description\":\"China's NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"width\":800,\"height\":600,\"caption\":\"Nmpa Approves First Clinical Trial Application Under Pilot Program Innovative Drugs\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Processus d&#039;examen et d&#039;approbation des nouveaux m\u00e9dicaments de la NMPA chinoise | RegASK","description":"La NMPA chinoise introduit un nouveau processus d&#039;examen et d&#039;approbation des m\u00e9dicaments, r\u00e9duisant le d\u00e9lai total d&#039;examen \u00e0 seulement 21 jours. Pour en savoir plus, rendez-vous sur RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/approbation-de-lexamen-des-medicaments-nmpa-en-chine\/","og_locale":"fr_FR","og_type":"article","og_title":"NMPA Approves First Clinical Trial Application Under Pilot Program for Innovative Drugs","og_description":"China's NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.","og_url":"https:\/\/regask.com\/fr\/approbation-de-lexamen-des-medicaments-nmpa-en-chine\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-12-02T12:58:50+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#article","isPartOf":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"NMPA Approves First Clinical Trial Application Under Pi&hellip;","datePublished":"2024-12-02T12:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/"},"wordCount":266,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","keywords":["Clinical Trial Regulations","Drug Development Regs","Oncology"],"articleSection":["Pharma and Biotech"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/","url":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/","name":"Processus d&#039;examen et d&#039;approbation des nouveaux m\u00e9dicaments de la NMPA chinoise | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","datePublished":"2024-12-02T12:58:50+00:00","description":"La NMPA chinoise introduit un nouveau processus d&#039;examen et d&#039;approbation des m\u00e9dicaments, r\u00e9duisant le d\u00e9lai total d&#039;examen \u00e0 seulement 21 jours. Pour en savoir plus, rendez-vous sur RegASK.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/china-nmpa-drug-review-approval\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","width":800,"height":600,"caption":"Nmpa Approves First Clinical Trial Application Under Pilot Program Innovative Drugs"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/7862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=7862"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/7862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/7872"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=7862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=7862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=7862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}